|
APOE KYOTO
|
APOE SENDAI
|
APOE-SUITA
|
APOE2 VARIANT
|
APOE2-DUNEDIN
|
APOE2-FUKUOKA
|
APOE3 VARIANT
|
APOE3(-)-FREIBURG
|
APOE3(-)-KOCHI
|
APOE3-WASHINGTON
|
APOE4 VARIANT
|
APOE4(+)
|
APOE4(-)-FREIBURG
|
APOLIPOPROTEINEMIA E1
|
DYSBETALIPOPROTEINEMIA DUE TO APOE2
|
FAMILIAL DYSBETALIPOPROTEINEMIA
|
HYPERCHOLESTEROLEMIA AND HYPERTRIGLYCERIDEMIA, TYPE III
|
HYPERLIPOPROTEINEMIA 3 (HLPP3)
|
HYPERLIPOPROTEINEMIA, TYPE III
|
HYPERLIPOPROTEINEMIA, TYPE III, ASSOCIATED WITH APOE DEFICIENCY
|
HYPERLIPOPROTEINEMIA, TYPE III, ASSOCIATED WITH APOE2
|
HYPERLIPOPROTEINEMIA, TYPE III, ASSOCIATED WITH APOE2-FUKUOKA
|
HYPERLIPOPROTEINEMIA, TYPE III, ASSOCIATED WITH APOE4
|
HYPERLIPOPROTEINEMIA, TYPE III, ASSOCIATED WITH APOE7
|
HYPERLIPOPROTEINEMIA, TYPE III, AUTOSOMAL DOMINANT
|
HYPERLIPOPROTEINEMIA, TYPE III, DUE TO APOE1-HARRISBURG
|
HYPERLIPOPROTEINEMIA, TYPE III, DUE TO APOE2-CHRISTCHURCH
|
HYPERLIPOPROTEINEMIA, TYPE III, DUE TO APOE4-PHILADELPHIA
|
LIPOPROTEIN GLOMERULOPATHY
|
LIPOPROTEIN GLOMERULOPATHY (LPG)
|